Search

Displaying results 1461 - 1470 of 10000 in total
  1. Drug

    Minaprine

    go.drugbank.com/drugs/DB00805
    Approved

    Minaprine is a psychotropic drug which has proved to be effective in the treatment of various depressive states. Like most antidepressants minaprine antagonizes behavioral despair. … Minaprine is an amino-phenylpyridazine antidepressant reported to be relatively free of cardiotoxicity, drowsiness, and weight gain.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Receptor Antagonists
  2. Drug

    Spirapril

    go.drugbank.com/drugs/DB01348
    ApprovedInvestigational

    Spirapril is an ACE inhibitor antihypertensive drug used to treat hypertension. Spirapril is converted to the active spiraprilat after administration.

    Categories: Agents Acting on the Renin-Angiotensin System
  3. Drug

    Ferrous bisglycinate

    go.drugbank.com/drugs/DB11210
    Approved

    It is found in foods for food enrichment or in supplements for the treatment of iron deficiency or iron deficiency anemia.

    Mixtures: healthy mamaBE WELL ROUNDED BE WELL ROUNDED, VINATAL DHA CAPSULA DE GELATINA BLANDA
  4. Drug

    Tenofovir alafenamide

    go.drugbank.com/drugs/DB09299
    ApprovedInvestigational

    Tenofovir alafenamide is a novel [tenofovir] prodrug developed in order to improve renal safety when compared to the counterpart [tenofovir disoproxil]. … [A178060] Both of these prodrugs were first created to cover the polar phosphonic acid group on tenofovir by using a novel oxycarbonyloxymethyl linkers to improve the oral bioavailability and intestinal

    Categories: Antivirals used in combination for the treatment of HIV infections
  5. Drug

    Zotepine

    go.drugbank.com/drugs/DB09225
    ApprovedWithdrawn

    [L1082] When the analysis of antipsychotics was retaken in 2016 by the FDA, zotepine did not reach the threshold effect to be further studied.[L1313]. … In 1993, it was classified as inactive drug substance (Status I, Type II) and in 1995 the FDA studied the manufacturing procedures of Zotepine tablets in Germany, but the status remained inactive.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Dopamine D2 Receptor Antagonists
  6. Drug

    Mepenzolate

    go.drugbank.com/drugs/DB04843
    ApprovedWithdrawn

    It has not been shown to be effective in contributing to the healing of peptic ulcer, decreasing the rate of recurrence, or preventing complications. … Mepenzolate also suppresses spontaneous contractions of the colon. Pharmacologically, it is a post-ganglionic parasympathetic inhibitor.

  7. Drug

    Lofexidine

    go.drugbank.com/drugs/DB04948
    ApprovedInvestigational

    Lofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992. … [T210] Lofexidine was then repurposed for the treatment of opioid withdrawal, as it was seen to be more economical and have fewer side effects than clonidine.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Receptor Agonists
  8. Drug

    Mebanazine

    go.drugbank.com/drugs/DB09248
    ApprovedWithdrawn

    Mebanazine, also known as _Actomol_, is a monoamine oxidase inhibitor (MAOI) belonging to the _hydrazine_ class of chemicals. … It was used in the past as an antidepressant in the 1960s, but has since been discontinued because of its hepatotoxic potential.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  9. Drug

    Rifamycin

    go.drugbank.com/drugs/DB11753
    ApprovedInvestigationalWithdrawn

    All of the derivatives have slight different physicochemical properties when compared to the parent structure. … [L4800] This drug was also sent for review to the EMA in 2015 by Dr. Falk Pharma Gmbh and it was granted a waiver for the tested conditions.[L4801]

  10. Drug

    Risperidone

    go.drugbank.com/drugs/DB00734
    ApprovedInvestigational

    [L12885] Risperidone binds with a very high affinity to 5-HT2A receptors, approximately 10-20 fold greater than the drug's binding affinity to D2 receptors, and carries lesser activity at several off-targets … Risperidone is thought to reduce this overactivity through inhibition of dopaminergic D2 receptors and serotonergic 5-HT2A receptors in the brain.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Adrenergic alpha-1 Receptor AntagonistsProducts: RISPERDAL QUICLKET ® TABLETAS DE 0.5 MG, RISPERDAL QUICKLET ® TABLETAS DE 2.0 MG